Structural basis of telomerase inhibition by the highly specific BIBR1532

Structure

Volumn 23, Issue 10, 2015, Pages 1934-1942

  Bryan, Christopher ^a,b   Rice, Cory ^a,b   Hoffman, Hunter ^a   Harkisheimer, Michael ^a   Sweeney, Melanie ^a,b   Skordalakes, Emmanuel ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIBR 1532; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; AMINOBENZOIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; INSECT PROTEIN; NAPHTHALENE DERIVATIVE; PROTEIN BINDING; RECOMBINANT PROTEIN; RNA; TERT PROTEIN, HUMAN;

APLASTIC ANEMIA; ARTICLE; CHROMOSOME ABERRATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG CONFORMATION; DRUG STRUCTURE; DYSKERATOSIS CONGENITA; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHOBICITY; METAPHASE; PRIORITY JOURNAL; PROTEIN MOTIF; RNA BINDING; SEQUENCE ALIGNMENT; SOUTHERN BLOTTING; TELOMERE HOMEOSTASIS; TRIBOLIUM CASTANEUM; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; MUTATION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; TRIBOLIUM; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; AMINOBENZOATES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ESCHERICHIA COLI; FIBROBLASTS; GENE EXPRESSION; HUMANS; INSECT PROTEINS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NAPHTHALENES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; RNA; TELOMERASE; TRIBOLIUM;

EID: 84943584136     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2015.08.006     Document Type: Article

References (39)

1. S.S. Banik, C. Guo, A.C. Smith, S.S. Margolis, D.A. Richardson, C.A. Tirado, and C.M. Counter C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity Mol. Cell Biol. 22 2002 6234 6246
2. C.J. Bley, X. Qi, D.P. Rand, C.R. Borges, R.W. Nelson, and J.J. Chen RNA-protein binding interface in the telomerase ribonucleoprotein Proc. Natl. Acad. Sci. USA 108 2011 20333 20338
3. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
4. K. Damm, U. Hemmann, P. Garin-Chesa, N. Hauel, I. Kauffmann, H. Priepke, C. Niestroj, C. Daiber, B. Enenkel, B. Guilliard, and et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation EMBO J. 20 2001 6958 6968
5. H. El-Daly, M. Kull, S. Zimmermann, M. Pantic, C.F. Waller, and U.M. Martens Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532 Blood 105 2005 1742 1749
6. T.M. Fletcher, M. Salazar, and S.F. Chen Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates Biochemistry 35 1996 15611 15617
7. T.M. Fletcher, B.E. Cathers, K.S. Ravikumar, B.M. Mamiya, and S.M. Kerwin Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate Bioorg. Chem. 29 2001 36 55
8. C.K. Garcia, W.E. Wright, and J.W. Shay Human diseases of telomerase dysfunction: insights into tissue aging Nucleic Acids Res. 35 2007 7406 7416
9. A.J. Gillis, A.P. Schuller, and E. Skordalakes Structure of the Tribolium castaneum telomerase catalytic subunit TERT Nature 455 2008 633 637
10. J. Gohring, N. Fulcher, J. Jacak, and K. Riha TeloTool: a new tool for telomere length measurement from terminal restriction fragment analysis with improved probe intensity correction Nucleic Acids Res. 42 2014 e21
11. D.E. Gomez, A.M. Tejera, and O.A. Olivero Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment Biochem. Biophys. Res. Commun. 246 1998 107 110
12. M. Goujon, H. McWilliam, W. Li, F. Valentin, S. Squizzato, J. Paern, and R. Lopez A new bioinformatics analysis tools framework at EMBL-EBI Nucleic Acids Res. 38 Suppl 2010 W695 W699
13. M. Hajek, N. Matulova, I. Votruba, A. Holy, and E. Tloust'ova Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates Biochem. Pharmacol. 70 2005 894 900
14. M. Harkisheimer, M. Mason, E. Shuvaeva, and E. Skordalakes A motif in the vertebrate telomerase N-terminal linker of TERT contributes to RNA binding and telomerase activity and processivity Structure 21 2013 1 9
15. C.B. Harley Telomerase and cancer therapeutics Nat. Rev. Cancer 8 2008 167 179
16. J. Holton, and T. Alber Automated protein crystal structure determination using ELVES Proc. Natl. Acad. Sci. USA 101 2004 1537 1542
17. S. Hossain, S. Singh, and N.F. Lue Functional analysis of the C-terminal extension of telomerase reverse transcriptase. A putative "thumb" domain J. Biol. Chem. 277 2002 36174 36180
18. J. Huang, A.F. Brown, J. Wu, J. Xue, C.J. Bley, D.P. Rand, L. Wu, R. Zhang, J.J. Chen, and M. Lei Structural basis for protein-RNA recognition in telomerase Nat. Struct. Mol. Biol. 21 2014 507 512
19. S. Huard, T.J. Moriarty, and C. Autexier The C terminus of the human telomerase reverse transcriptase is a determinant of enzyme processivity Nucleic Acids Res. 31 2003 4059 4070
20. L.H. Hurley, R.T. Wheelhouse, D. Sun, S.M. Kerwin, M. Salazar, O.Y. Fedoroff, F.X. Han, H. Han, E. Izbicka, and D.D. Von Hoff G-quadruplexes as targets for drug design Pharmacol. Ther. 85 2000 141 158
21. M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, H. McWilliam, F. Valentin, I.M. Wallace, A. Wilm, R. Lopez, and et al. ClustalW and ClustalX version 2 Bioinformatics 23 2007 2947 2948
22. X. Liu, H. Takahashi, Y. Harada, T. Ogawara, Y. Ogimura, Y. Mizushina, M. Saneyoshi, and T. Yamaguchi 3′-Azido-2′,3′-dideoxynucleoside 5′-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells Nucleic Acids Res. 35 2007 7140 7149
23. M. Mitchell, A. Gillis, M. Futahashi, H. Fujiwara, and E. Skordalakes Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA Nat. Struct. Mol. Biol. 17 2010 513 518
24. J. Murakami, N. Nagai, K. Shigemasa, and K. Ohama Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines Eur. J. Cancer 35 1999 1027 1034
25. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
26. S. Neidle, and M.A. Read G-quadruplexes as therapeutic targets Biopolymers 56 2000 195 208
27. E. Pascolo, C. Wenz, J. Lingner, N. Hauel, H. Priepke, I. Kauffmann, P. Garin-Chesa, W.J. Rettig, K. Damm, and A. Schnapp Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate J. Biol. Chem. 277 2002 15566 15572
28. Y. Peng, I.S. Mian, and N.F. Lue Analysis of telomerase processivity: mechanistic similarity to HIV-1 reverse transcriptase and role in telomere maintenance Mol. Cell 7 2001 1201 1211
29. S. Rouda, and E. Skordalakes Structure of the RNA-binding domain of telomerase: implications for RNA recognition and binding Structure 15 2007 1403 1412
30. A. Sauerwald, S. Sandin, G. Cristofari, S.H. Scheres, J. Lingner, and D. Rhodes Structure of active dimeric human telomerase Nat. Struct. Mol. Biol. 20 2013 454 460
31. J.W. Shay, and W.E. Wright Telomerase: a target for cancer therapeutics Cancer Cell 2 2002 257 265
32. J.W. Shay, and W.N. Keith Targeting telomerase for cancer therapeutics Br. J. Cancer 98 2008 677 683
33. K. Steczkiewicz, M.T. Zimmermann, M. Kurcinski, B.A. Lewis, D. Dobbs, A. Kloczkowski, R.L. Jernigan, A. Kolinski, and K. Ginalski Human telomerase model shows the role of the TEN domain in advancing the double helix for the next polymerization step Proc. Natl. Acad. Sci. USA 108 2011 9443 9448
34. C. Strahl, and E.H. Blackburn The effects of nucleoside analogs on telomerase and telomeres in tetrahymena Nucleic Acids Res. 22 1994 893 900
35. T. Yamaguchi, M. Kawarai, Y. Takeshita, F. Ishikawa, and M. Saneyoshi Inhibition of human telomerase by nucleotide analogues bearing a hydrophobic group Nucleic Acids Symp. Ser. 2000 175 176
36. H. Yamaguchi, R.T. Calado, H. Ly, S. Kajigaya, G.M. Baerlocher, S.J. Chanock, P.M. Lansdorp, and N.S. Young Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia N. Engl. J. Med. 352 2005 1413 1424
37. T. Yamaguchi, X. Liu, T. Ogawara, M. Inomata, and M. Saneyoshi Telomerase inhibition by 3′-azido-2′, 3′-dideoxynucleoside 5′-triphosphates and telomere shortening in human cultured cells by the corresponding nucleosides Nucleic Acids Symp. Ser. 2004 2006 271 272
38. Y.E. Yegorov, D.N. Chernov, S.S. Akimov, N.L. Bolsheva, A.A. Krayevsky, and A.V. Zelenin Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts FEBS Lett. 389 1996 115 118
39. Y.E. Yegorov, D.N. Chernov, S.S. Akimov, A.K. Akhmalisheva, Y.B. Smirnova, D.B. Shinkarev, I.V. Semenova, I.N. Yegorova, and A.V. Zelenin Blockade of telomerase function by nucleoside analogs Biochemistry (Mosc) 62 1997 1296 1305